PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Metsä Board Oyj (METSA.HE)
5.580.04 (-0.71%)
5.38 - 5.60
4.95 - 8.28
2.3K / 2.4K (Avg.)
-279.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.08%
Revenue growth above 1.5x STERV.HE's 2.71%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
120.47%
Gross profit growth above 1.5x STERV.HE's 13.12%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
26.84%
EBIT growth 50-75% of STERV.HE's 50.42%. Martin Whitman would suspect suboptimal resource allocation.
26.84%
Operating income growth at 50-75% of STERV.HE's 50.42%. Martin Whitman would doubt the firm’s ability to compete efficiently.
28.03%
Net income growth under 50% of STERV.HE's 57.47%. Michael Burry would suspect the firm is falling well behind a key competitor.
25.00%
EPS growth under 50% of STERV.HE's 59.09%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
25.00%
Diluted EPS growth under 50% of STERV.HE's 59.09%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.58%
Slight or no buybacks while STERV.HE is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.58%
Slight or no buyback while STERV.HE is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-71.54%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-74.46%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-27.12%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
2.43%
Positive 5Y CAGR while STERV.HE is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
-15.16%
Negative 3Y CAGR while STERV.HE stands at 3.53%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
497.93%
10Y OCF/share CAGR above 1.5x STERV.HE's 268.84%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-23.94%
Negative 5Y OCF/share CAGR while STERV.HE is at 3250.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-15.81%
Negative 3Y OCF/share CAGR while STERV.HE stands at 142.31%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
143.23%
Net income/share CAGR at 50-75% of STERV.HE's 286.06%. Martin Whitman might question if the firm’s product or cost base lags behind.
650.00%
Below 50% of STERV.HE's 1711.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
66.67%
3Y net income/share CAGR 50-75% of STERV.HE's 112.40%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
52.10%
5Y equity/share CAGR above 1.5x STERV.HE's 6.41%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
10.56%
3Y equity/share CAGR at 50-75% of STERV.HE's 15.10%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
No Data
No Data available this quarter, please select a different quarter.
18.92%
AR growth well above STERV.HE's 5.54%. Michael Burry fears inflated revenue or higher default risk in the near future.
3.95%
Inventory shrinking or stable vs. STERV.HE's 18.46%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
3.61%
Asset growth above 1.5x STERV.HE's 0.45%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-2.92%
We have a declining book value while STERV.HE shows 2.21%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
7.18%
Debt growth far above STERV.HE's 2.95%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-100.00%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-3.68%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.